CONSHOHOCKEN, PA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)BIOADVANCE CAPITAL, founded in 2002, is a community nonprofit in the Youth Development sector that reported $7.8M in total revenue in fiscal year 2024. Revenue grew 9% year-over-year, indicating healthy expansion. The organization ran a surplus of $5.1M, a strong 65% operating margin.
BIOADVANCE CAPITAL (FORMERLY BIOADVANCE) WAS ESTABLISHED IN 2001 AS ONE OF THE THREE LIFE SCIENCES GREENHOUSES FUNDED WITH A SHARE OF PENNSYLVANIA'S NATIONAL TOBACCO SETTLEMENT REVENUES TO PROMOTE HUMAN HEALTH BY SUPPORTING BIOMEDICAL INNOVATION IN SOUTHEASTERN PENNSYLVANIA. THE ORGANIZATION DEDICATED $25 MILLION OF THE ORIGINAL GRANT FUNDING TO PRE SEED AND EARLY STAGE INVESTMENTS TO HELP ADVANCE TECHNOLOGIES TO THE NEXT STAGE OF DEVELOPMENT. SINCE THE ORIGINAL GRANT FUNDING WAS EXPENDED, BIOADVANCE CAPITAL HAS CONTINUED TO SUPPORT EMERGING LIFE SCIENCES COMPANIES IN SOUTHEASTERN PENNSYLVANIA AND THE SURROUNDING MID ATLANTIC REGION, WITH A FOCUS ON TECHNOLOGIES THAT IMPROVE HUMAN HEALTH.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $7,785,105 | $7,128,753 | +0.1% |
| Expenses | $2,686,198 | $2,624,935 | +0.0% |
| Net Income | $5,098,907 | $4,503,818 | +0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| SHAHRAM HEJAZI | CEO & MANAGING DIRECTOR | 32.00 |
Officer
Director
|
$392,987 | $60,625 | $453,612 |
| JEN GILBURG | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| PHILIP GERBINO PHARMD | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| ROY M ROSIN | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| LAUREN LENFEST | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| STEVEN NICHTBERGER MD | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| BARBARA S SCHILBERG | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| DR JOHN EPSTEIN | DIRECTOR (EFF 6/13/25) | 0.50 |
Director
|
$0 | $0 | $0 |
| DR MARIE LINDNER | DIRECTOR (EFF 6/13/25) | 0.50 |
Director
|
$0 | $0 | $0 |
| GREG HARRIMAN | VP AND ASST SECRETARY | 24.00 |
Officer
|
$240,026 | $10,890 | $250,916 |
| DAVID SHIN | COO AND SECRETARY | 40.00 |
Officer
|
$332,509 | $0 | $332,509 |
| FREDERICK JONES | ADVISORY PARTNER | 24.00 |
Highest
|
$169,199 | $14,030 | $183,229 |
| ROBERT DRISCOLL | DIRECTOR OF FINANCE | 40.00 |
Highest
|
$250,203 | $49,744 | $299,947 |
| MARNIE MCCOY | PROGRAM DIRECTOR | 40.00 |
Highest
|
$157,234 | $18,773 | $176,007 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $7,785,105 | $2,686,198 | $86,406,908 | $5,098,907 |
| 2024 | $7,128,753 | $2,624,935 | $81,128,530 | $4,503,818 |
| 2023 | $1,586,292 | $2,508,519 | $81,948,557 | $-922,227 |
| 2022 | $2,523,586 | $2,278,521 | $73,104,917 | $245,065 |
| 2021 | $2,931,752 | $2,412,456 | $80,190,811 | $519,296 |
| 2020 | $12,959,074 | $2,328,525 | $78,551,910 | $10,630,549 |
| 2020 | $12,959,074 | $2,328,525 | $78,551,910 | $10,630,549 |
| 2019 | $2,558,906 | $2,427,191 | $66,045,472 | $131,715 |
| 2019 | $2,558,906 | $2,427,191 | $66,045,472 | $131,715 |
| 2018 | $2,635,201 | $2,254,734 | $60,326,743 | $380,467 |
Compare BIOADVANCE CAPITAL with other nonprofits in Pennsylvania and across the country.